# EDGAR Filing Document

**Accession Number:** 0001739104
**File Stem:** 0001104659-23-008591
**Filing Date:** 2023-1
**Character Count:** 4805
**Document Hash:** d02c329de15119494dcb08616ce072b5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-008591.hdr.sgml**: 20230131

**ACCESSION NUMBER**: 0001104659-23-008591

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20230131

**ITEM INFORMATION**: Other Events

**FILED AS OF DATE**: 20230131

**DATE AS OF CHANGE**: 20230131

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Elanco Animal Health Inc
- **CENTRAL INDEX KEY:** 0001739104
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 825497352
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38661
- **FILM NUMBER:** 23572573

**BUSINESS ADDRESS:**
- **STREET 1:** 2500 INNOVATION WAY
- **CITY:** GREENFIELD
- **STATE:** IN
- **ZIP:** 46140
- **BUSINESS PHONE:** 877-352-6261

**MAIL ADDRESS:**
- **STREET 1:** 2500 INNOVATION WAY
- **CITY:** GREENFIELD
- **STATE:** IN
- **ZIP:** 46140

?xml version="1.0" encoding="utf-8"?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington** **, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of Earliest Event Reported): **January 31, 2023**

**Elanco Animal Health Incorporated**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Indiana** | **001-38661** | **82-5497352** |
| (State or other jurisdiction <br> of incorporation) | (Commission <br> File Number) | (I.R.S. Employer<br> Identification No.) |

---

---

| | |
|:---|:---|
| **2500 Innovation Way**<br> **Greenfield, Indiana**<br> (Address of principal executive offices) | **46140**<br> (Zip Code) |

---

Registrant's telephone number, including area code: **(877) 352-6261**

**Not Applicable**

(Former Name or Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

◻ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

◻ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

◻ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

◻ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | &nbsp;&nbsp;**Trading Symbol(s)** | &nbsp;&nbsp;**Name of each exchange on which<br> registered** |
| Common stock, no par value | &nbsp;&nbsp;ELAN | &nbsp;&nbsp;New York Stock Exchange |
| 5.00% Tangible Equity Units | &nbsp;&nbsp;ELAT | &nbsp;&nbsp;New York Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

◻ Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

---

| | |
|:---|:---|
| **Item 8.01** | **Other Events.** |

---

On January 31, 2022, Elanco Animal Health Incorporated ("Elanco") announced the settlement rate for the prepaid stock purchase contracts that are components of its outstanding 5.00% Tangible Equity Units (the "Units") issued in January 2020. On February 1, 2023, holders will receive 1.5625 shares of Elanco's common stock, no par value per share (the "Common Stock"), for each prepaid stock purchase contract that they hold, with cash to be paid in lieu of any fractional shares. Accordingly, upon settlement of all outstanding prepaid stock purchase contracts, Elanco expects to issue an aggregate of approximately 17.2 million shares of Common Stock. On February 1, 2023, Elanco will also make the final installment payment on the amortizing notes that are the other component of the Units. The Units will then cease to be outstanding.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | Elanco Animal Health Incorporated | Elanco Animal Health Incorporated |
| Date: January 31, 2023 | *By:* | /s/ Todd Young |
|  |  | *Name:* Todd Young |
|  |  | *Title:* Executive Vice President and Chief Financial Officer |

---